Source: Healio.com/hematology-oncology, April 2016

NEW YORK — Christian Blank, MD, PhD, staff member in medical oncology and group leader of the division of immunology at Netherlands Cancer Institute, reviewed new checkpoint targets during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.

Evidence suggests checkpoint modulation will be the backbone of melanoma therapy, Blank said.

“We have treated a lot of patients with immunotherapy and we have treated a lot of patients with targeted therapy,” Blank said. “I am convinced that, for long-term benefit, we need immunotherapy.”